Ge Li

Title: Ge Li: Innovator in Biomedicine

Introduction

Ge Li is a prominent inventor based in Jiangsu, China. He has made significant contributions to the field of biomedicine, particularly in the development of humanized monoclonal antibodies. With a total of 2 patents, his work focuses on innovative solutions for cancer treatment.

Latest Patents

Ge Li's latest patents include the "Anti-human PD-L1 humanized monoclonal antibody and application thereof." This invention relates to the biomedicine field and aims to provide an antibody that specifically binds to human PD-L1, enhancing T-cell activation and significantly inhibiting tumor growth. Another notable patent is the "Anti-human PD-1 humanized monoclonal antibody and application thereof." This invention also targets the biomedicine sector, offering an antibody that binds to human PD-1, blocking the interaction with PD-L1 and partially restoring T-cell functions, which can lead to a reduction in tumor growth.

Career Highlights

Ge Li is associated with Reyoung (Suzhou) Biology Science & Technology Co., Ltd., where he continues to advance his research and development efforts. His work has positioned him as a key figure in the biomedicine industry, contributing to innovative therapies for cancer treatment.

Collaborations

Ge Li collaborates with notable colleagues, including Yixiang Zhu and Shuhua Guo. Their combined expertise enhances the research and development efforts within their organization.

Conclusion

Ge Li's contributions to biomedicine through his innovative patents demonstrate his commitment to advancing cancer treatment. His work continues to impact the field significantly, showcasing the importance of research and collaboration in developing effective therapies.